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PARTICIPANTS WHO WOULD BENEFIT: Members
of P&T, MCO and others assessing formulary inclusion
and cost-benefits of asthma therapies. Asthma has in-
creased 10-fold in the last 2 decades, costing $6 B/year in
the US. The most severe asthmatics account for the majority
of the total health care costs, endpoints involving emergency
department treatment ($250) and hospital admission
($3100). Anti-inflammatories (steroids, leukotriene modifi-
ers) are recommended for most levels of asthma severity and
should be able to alter these endpoints. However, initial pre-
scription filling (50–80%) and refilling (20–40%) rates are
so poor as to preclude comparisons of drug effectiveness
or health care plans. While disease management of asthma
would wish to alter these endpoint costs, it is not possible
to develop a PD-PE model to compare effectiveness of
asthma anti-inflammatories across or within plans.
OBJECTIVES: To develop a PD-PE model to compare ef-
fectiveness of anti-inflammatory therapies. To obviate the
above limitations, we used published clinical results in-
volving moderate-severe asthmatics in terms of improved
lung function ((0.1L FEV1) calibrated against the anti-
inflammatory inhaled therapy costs (per-day  treatment
duration). Additional cost reductions related to reduced
need for metered dose inhalers were also tabulated.
RESULTS: These analyses show $US costs to achieve a
0.1L improvement in moderate-severe asthmatics using
steroids such as budesonide ($232) or beclomethasone
($110), leukotriene modifiers (zileuton $68 or montelukast
$101), as well as the single isomer -agonist levalbuterol
($39). Chronic treatment with racemic albuterol did not
improve lung function but rather resulted in a decrease in
lung function. Each final cost is inclusive of reduced al-
buterol metered dose inhaler costs.
CONCLUSIONS: This cross-stratified PD-PE model as-
sessed anti-inflammatory therapy impact on improvements
in asthma lung function and reduced need for rescue MDI.
As these results are derived from well-controlled clinical
studies, they reflect optimized treatment compliance and
therefore maximal PD-PE effect. Accordingly, these rela-
tive scores may provide insights relating to formulary in-
clusion of drugs which face class competition.
ECONOMIC AND OUTCOMES ISSUES OF 
GASTROINTESTINAL DISORDERS
PGI1
EFFECTIVENESS OF OMEPRAZOLE, 
AMOXICILLIN, AND CLARITHROMYCIN IN 
ERADICATING HELICOBACTER PYLORI IN 
PATIENTS ON CHRONIC ACID SUPPRESSION 
FOR PEPTIC ULCER DISEASE OR
ULCER-LIKE SYMPTOMS
Allison J, Hiatt R, Levin TR, Lieu T, Ackerson L, Hurley L, 
Libran D
Kaiser Permanente Division of Research, Oakland, CA, USA
OBJECTIVE: To evaluate the effectiveness of the omepra-
zole, amoxicillin, and clarithromycin (OAC) regimen in
eradicating H. pylori (HP) in patients on long term acid
suppression medicine for documented ulcer or ulcer like
symptoms.
METHODS: Kaiser Permanente data bases were accessed
to identify all patients receiving acid suppression therapy
for at least three 30-day periods within the most recent 12-
month time frame. Those identified were then matched to
databases that capture physician recorded diagnoses at
each patient visit. Patients not previously treated for HP
and with documented (by endoscopy or UGI) diagnoses of
duodenal ulcer (DU), gastric ulcer (GU), gastritis, and un-
specified peptic ulcer disease (PUD) or ulcer like symptoms
were selected for recruitment. Study participants were ran-
domly assigned to C14 urea breath testing (UBT) and HP
eradication, if positive, versus standard maintenance acid
suppressive therapy. All patients positive on UBT (except
those allergic to penicillin N  12) were treated with ome-
prazole 20 mg, amoxicillin 1gm, clarithromycin 500 mg
bid for 10 days. Proof of eradication was documented by
UBT administered 4 weeks post treatment. Each patient
testing negative after treatment was taken off acid reduc-
ing medication and followed for up to one year.
RESULTS: Ninety-five of 96 patients completed 10 days
of OAC, and 89 have been retested 4 weeks later. Of those
retested, 85% (95% CI  76%, 92%) were breath test
negative and 15% (95% CI  8%, 24%) were breath test
positive. Fourteen participants reported recurrent symp-
toms following HP eradication. Side effects of patients on
the regimen were reported by 6 out of 96 treated (6%),
and included bloody diarrhea (1), rash (4), and abdominal
cramps (2).
CONCLUSION: OAC is an effective regimen for eradicat-
ing HP in infected patients on chronic acid suppression for
PUD or ulcer like symptoms. Compliance with the regi-
men is high and serious adverse reactions are low.
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PURPOSE: To assess the cost of care associated with the
treatment of constipation subjects.
METHODS: All subjects contained within PharMetrics In-
tegrated Outcomes database possessing an ICD-9-CM 
564.0 between January 1, 1996 and March 31, 1998 were
eligible for study inclusion. Subjects were required to have
data available for analysis 6 months preceding and follow-
ing the date of their constipation diagnosis. Charge data
were evaluated over the 6-month intervals surrounding the
index date. Additionally, monthly charges were plotted
over the entire 12-month interval to allow examination of
trends associated with the diagnosis and treatment of con-
